Contineum Therapeutics Inc (CTNM) FinancialsCTNMFinancialContineum Therapeutics Inc

Evaluating the bottom line, Contineum Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -28.01%, provide a clear picture of how effectively CTNM converts its operational activities into shareholder value.

In the context of the broader market, CTNM competes directly with industry leaders such as CRMD and AGMB. With a market capitalization of $533.84M, it holds a significant position in the sector. When comparing efficiency, CTNM's gross margin of N/A stands against CRMD's 75.66% and AGMB's N/A. Such benchmarking helps identify whether Contineum Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Contineum has faced consistent net losses, with a net income of -$15.154 million reported for Q2 2026. The company has a current ratio of 37.17, indicating excellent liquidity, and a negative P/E ratio of -11.27, reflecting ongoing profitability challenges.